634 related articles for article (PubMed ID: 31633853)
1. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
[TBL] [Abstract][Full Text] [Related]
4. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
[TBL] [Abstract][Full Text] [Related]
5. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
8. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
10. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
[TBL] [Abstract][Full Text] [Related]
12. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.
Vickerman P; Martin N; Turner K; Hickman M
Addiction; 2012 Nov; 107(11):1984-95. PubMed ID: 22564041
[TBL] [Abstract][Full Text] [Related]
13. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
14. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ
J Hepatol; 2021 Feb; 74(2):293-302. PubMed ID: 32931879
[TBL] [Abstract][Full Text] [Related]
15. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.
Lafferty L; Wild TC; Rance J; Treloar C
Harm Reduct J; 2018 Aug; 15(1):39. PubMed ID: 30075728
[TBL] [Abstract][Full Text] [Related]
16. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
17. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
18. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
19. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of hepatitis C virus among prisoners in Scotland.
Taylor A; Munro A; Allen E; Dunleavy K; Cameron S; Miller L; Hickman M
Addiction; 2013 Jul; 108(7):1296-304. PubMed ID: 23297816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]